Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Myeloma treatment and prognosis

2nd ecancer – TMC Kolkata Oncology Congress

30 Sep - 1 Oct 2023

Published: 10 Oct 2023

Views: 2469

Rating:

Save

Dr Maitreyyee Bhattacharyya - Institute of Hematology and Transfusion medicine, Medical College, Kolkata

Dr Maitreyyee Bhattacharyya speaks at the 2nd ecancer TMC Oncology Congress, which was held at the Tata Medical Center, Kolkata, on 31 September and 1 October 2023.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

2 year recurrence free survival benefit for resectable melanoma treated with...

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )

Adjuvant radiotherapy has no benefit following radical prostatectomy

Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK

Adjuvant radiotherapy has no benefit following radical prostatectomy ( Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK )

The advantages of IORT for early breast cancer treatment

Dr David Martinez Perez - AUNA, Lima, Peru

The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )

Global adoption of single-shot targeted IORT for breast cancer

Dr Jayant Vaidya - University College London, London, UK

Global adoption of single-shot targeted IORT for breast cancer ( Dr Jayant Vaidya - University College London, London, UK )

The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation...

Dr Jayant Vaidya - University College London, London, UK

The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival ( Dr Jayant Vaidya - University College London, London, UK )

Hypofractionated high dose intensity modulated radiotherapy non-inferior for...

Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK

$Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer ( Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK )$

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer

Dr Hope Rugo - University of California San Francisco, San Francisco, USA

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )

More from ecancer